Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan
International Journal of Urology · 2024
DOI: 10.1111/iju.15435 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2024. Verfasst von Takuto Hara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Antibodies, Monoclonal, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
ORCID-Profile: Takuto Hara, Yuto Matsushita, Kenichi Harada, Naohiro Fujimoto
Zitieren
APA
Hara, T., Matsushita, Y., Harada, K., Fujimoto, N., Fujisawa, M., & Miyake, H. (2024). Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15435
Vancouver
Hara T, Matsushita Y, Harada K, Fujimoto N, Fujisawa M, Miyake H. Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan. International Journal of Urology. 2024. doi:10.1111/iju.15435
BibTeX
@article{Hara2024,
author = {Hara, Takuto and Matsushita, Yuto and Harada, Kenichi and Fujimoto, Naohiro and Fujisawa, Masato and Miyake, Hideaki},
title = {Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15435}
}
EUVIMED